2026-2034年全球口服糖尿病治療藥物市場規模、佔有率、趨勢和成長分析報告

預計口服糖尿病藥物的市場規模將從 2025 年的 469.7 億美元成長到 2034 年的 685.5 億美元，2026 年至 2034 年的複合年成長率為 4.29%。

受人口老化、都市化和生活型態改變等因素推動，全球第二型糖尿病盛行率不斷上升，口服降血糖藥市場顯著擴張。二甲雙胍、磺醯尿素、DPP-4抑制劑、SGLT2抑制劑以及新型固定劑量組合藥物製劑等關鍵治療藥物類別不斷豐富治療選擇。診斷率的提高、推薦聯合治療的指南修訂以及慢性病門診管理模式的轉變，都促進了市場成長。儘管現有分子藥物的非專利滲透率較高，導致銷量仍保持高位，但新品牌藥已佔據了較高的市場佔有率。

推動成長的因素包括糖尿病盛行率的上升、篩檢和診斷範圍的擴大，以及臨床醫生對能夠改善心血管和腎臟預後的藥物的偏好。保險覆蓋範圍的擴大和價格合理的學名藥的普及，提高了許多地區患者的用藥可及性。製藥公司的研發重點是具有多重療效（例如減肥、心臟保護作用）的藥物和固定劑量組合藥物透過提高用藥依從性和簡化治療方法，儘管在某些市場面臨價格壓力，但仍提升了市場價值。

展望未來，預計將出現向個人化醫療的轉變，這種轉變將納入合併症情況和成本效益考量。整合生物感測器和數位技術的護理模式有望透過將口服藥物與監測相結合來改善治療效果。隨著專利到期，學名藥的競爭將加劇，但新型小分子化合物和聯合治療將開闢新的市場領域。市場成長將取決於能否在可負擔性、長期治療效果數據以及醫療系統容納不斷成長的患者數量的能力之間取得平衡。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球口服糖尿病治療藥物市場：依藥物類別分類

• 市場分析、洞察與預測
• 雙胍類藥物
• Dipeptidyl Peptidase-4 (DPP-4) 抑制劑
• 鈉-葡萄糖共同輸送體2 (SGLT-2) 抑制劑
• 磺醯尿素類藥物
• 胰島素增敏劑藥物
• Meglitinides類藥物
• α-Glucosidase酶抑制劑
• 其他藥物類別

第5章 全球口服糖尿病治療藥物市場：依疾病類型分類

• 市場分析、洞察與預測
• 2型糖尿病
• 1型糖尿病

第6章 全球口服糖尿病治療市場：依藥物類型分類

• 市場分析、洞察與預測
• 品牌商品
• 非專利的

第7章 全球口服糖尿病治療藥物市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第8章 全球口服糖尿病治療藥物市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Astellas Pharma
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Eli Lilly And Company
  • Glenmark Pharmaceuticals
  • Johnson & Johnson（Janssen Pharmaceuticals）
  • Merck
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Sanofi
  • Takeda Pharmaceuticals

The Oral Anti-Diabetic Drug Market size is expected to reach USD 68.55 Billion in 2034 from USD 46.97 Billion (2025) growing at a CAGR of 4.29% during 2026-2034.

The oral anti-diabetic drug market expanded substantially with the rising global prevalence of type 2 diabetes, driven by ageing populations, urbanization, and lifestyle changes. Key therapeutic classes-metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, and newer fixed-dose combinations-have broadened treatment options. Market growth was supported by improved diagnosis rates, guideline updates favoring combination therapy, and the shift to chronic outpatient management. Generic penetration for older molecules kept unit volumes high while branded novel agents captured premium shares.

Drivers of growth include increasing diabetes prevalence, greater screening and diagnosis, and clinician preference for drugs with cardiovascular and renal outcome benefits. Payer coverage expansions and the availability of affordable generics have widened patient access in many regions. Pharmaceutical R&D focusing on agents with multifactorial benefits (weight loss, cardioprotection) along with fixed-dose combination pills has encouraged adherence and simplified regimens, lifting market value despite pricing pressures in some markets.

Looking forward, the market will likely evolve toward personalized therapy incorporating comorbidity profiles and cost-effectiveness. Biosensor- and digital-integrated care models may pair oral therapies with monitoring to improve outcomes. Patent expirations of some branded agents will increase generic competition, while novel small molecules and combination therapies could capture new segments. Market growth will hinge on balancing affordability, long-term outcome data, and healthcare system capacity to manage expanding patient numbers.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Biguanides
• Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors
• Sodium-Glucose Transport Protein-2 (Sglt-2) Inhibitors
• Sulfonylureas
• Thiazolidinediones
• Meglitinides
• Alpha-Glucosidase Inhibitors
• Other Drug Classes

By Disease Type

• Type 2 Diabetes
• Type 1 Diabetes

By Medication Type

• Branded
• Generic

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Glenmark Pharmaceuticals, Johnson Johnson Janssen Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda Pharmaceuticals

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Biguanides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Dipeptidyl Peptidase-4 (Dpp-4) Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Sodium-Glucose Transport Protein-2 (Sglt-2) Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Sulfonylureas Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Thiazolidinediones Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Meglitinides Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Alpha-Glucosidase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Type
• 5.2. Type 2 Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Type 1 Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BY MEDICATION TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Medication Type
• 6.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Generic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ORAL ANTI-DIABETIC DRUG MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Class
  • 8.2.2 By Disease Type
  • 8.2.3 By Medication Type
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Class
  • 8.3.2 By Disease Type
  • 8.3.3 By Medication Type
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Class
  • 8.4.2 By Disease Type
  • 8.4.3 By Medication Type
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Class
  • 8.5.2 By Disease Type
  • 8.5.3 By Medication Type
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Class
  • 8.6.2 By Disease Type
  • 8.6.3 By Medication Type
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ORAL ANTI-DIABETIC DRUG INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Astellas Pharma
  • 10.2.2 AstraZeneca
  • 10.2.3 Bayer
  • 10.2.4 Boehringer Ingelheim
  • 10.2.5 Bristol Myers Squibb
  • 10.2.6 Eli Lilly And Company
  • 10.2.7 Glenmark Pharmaceuticals
  • 10.2.8 Johnson & Johnson (Janssen Pharmaceuticals)
  • 10.2.9 Merck
  • 10.2.10 Novartis
  • 10.2.11 Novo Nordisk
  • 10.2.12 Pfizer
  • 10.2.13 Sanofi
  • 10.2.14 Takeda Pharmaceuticals